PH30305A - Improved meningococcal polysaccharide conjugate vaccine - Google Patents

Improved meningococcal polysaccharide conjugate vaccine

Info

Publication number
PH30305A
PH30305A PH41724A PH41724A PH30305A PH 30305 A PH30305 A PH 30305A PH 41724 A PH41724 A PH 41724A PH 41724 A PH41724 A PH 41724A PH 30305 A PH30305 A PH 30305A
Authority
PH
Philippines
Prior art keywords
conjugate vaccine
polysaccharide conjugate
meningococcal polysaccharide
improved
improved meningococcal
Prior art date
Application number
PH41724A
Other languages
English (en)
Inventor
Harold J Jennings
Francis Michon
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of PH30305A publication Critical patent/PH30305A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PH41724A 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine PH30305A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
PH30305A true PH30305A (en) 1997-02-20

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
PH41724A PH30305A (en) 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine

Country Status (30)

Country Link
US (3) US5576002A (enExample)
EP (1) EP0504202B1 (enExample)
JP (1) JP2637845B2 (enExample)
KR (1) KR0158436B1 (enExample)
CN (4) CN1049223C (enExample)
AR (1) AR243934A1 (enExample)
AT (1) ATE121947T1 (enExample)
AU (1) AU641715B2 (enExample)
BR (1) BR9007917A (enExample)
CA (1) CA2071811C (enExample)
CZ (1) CZ283530B6 (enExample)
DE (1) DE69019164T2 (enExample)
DK (1) DK0504202T3 (enExample)
ES (1) ES2071288T3 (enExample)
FI (2) FI104539B (enExample)
HR (1) HRP920872A2 (enExample)
HU (2) HU9201966D0 (enExample)
IE (1) IE68414B1 (enExample)
IL (1) IL96676A (enExample)
IN (1) IN171747B (enExample)
NO (2) NO305275B1 (enExample)
NZ (1) NZ236471A (enExample)
PH (1) PH30305A (enExample)
PL (2) PL166659B1 (enExample)
RO (1) RO111416B1 (enExample)
RU (1) RU2105568C1 (enExample)
SI (1) SI20008B (enExample)
WO (1) WO1991008772A1 (enExample)
YU (1) YU24391A (enExample)
ZA (1) ZA9010065B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
EP0667787B1 (en) * 1992-09-24 2001-07-18 Brigham And Women's Hospital Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
DE69615362T3 (de) * 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
US6048527A (en) * 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Neisseria meningitidis血清型B複合糖質およびその使用法
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
EP1007546B1 (en) * 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal b epitopes
ES2346022T3 (es) 1997-12-23 2010-10-07 Baxter Healthcare S.A. Procedimiento para la extraccion y el aislamiento de polisacaridos capsulares bacterianos para su uso como vacunas o ligandos a proteinas como vacunas de conjugados.
PL346645A1 (en) * 1998-08-19 2002-02-25 North American Vaccine IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
CN1263510C (zh) * 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
RU2322451C2 (ru) * 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
BR0308768A (pt) * 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
RU2378008C2 (ru) * 2002-05-14 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004089407A2 (en) * 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
AU2005258301A1 (en) 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2007000341A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
EP2387417B1 (en) 2009-01-16 2016-05-11 University of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有psa組成物、その単離の方法および使用の方法
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.

Also Published As

Publication number Publication date
ZA9010065B (en) 1992-02-26
JPH05505392A (ja) 1993-08-12
EP0504202A1 (en) 1992-09-23
AU641715B2 (en) 1993-09-30
RU2105568C1 (ru) 1998-02-27
US5683699A (en) 1997-11-04
BR9007917A (pt) 1992-10-20
FI104539B (fi) 2000-02-29
DK0504202T3 (da) 1995-10-02
IL96676A0 (en) 1991-09-16
DE69019164D1 (de) 1995-06-08
NO973311L (no) 1992-08-14
CN1055541A (zh) 1991-10-23
PL166659B1 (pl) 1995-06-30
IN171747B (enExample) 1992-12-26
RO111416B1 (ro) 1996-10-31
NO922316L (no) 1992-08-14
US5902586A (en) 1999-05-11
CN1036522C (zh) 1997-11-26
AR243934A1 (es) 1993-09-30
HU9201966D0 (en) 1992-10-28
FI922737A0 (fi) 1992-06-12
NZ236471A (en) 1992-10-28
NO305275B1 (no) 1999-05-03
PL166035B1 (pl) 1995-03-31
CN1096516A (zh) 1994-12-21
HRP920872A2 (en) 1997-06-30
KR0158436B1 (ko) 1998-12-01
CZ283530B6 (cs) 1998-04-15
IE904513A1 (en) 1991-06-19
HUT64480A (en) 1994-01-28
HU218146B (hu) 2000-06-28
CA2071811A1 (en) 1991-06-15
CZ628490A3 (en) 1997-12-17
NO922316D0 (no) 1992-06-12
EP0504202B1 (en) 1995-05-03
CN1100428A (zh) 1995-03-22
ES2071288T3 (es) 1995-06-16
DE69019164T2 (de) 1995-09-07
WO1991008772A1 (en) 1991-06-27
CA2071811C (en) 2003-11-04
PL288271A1 (en) 1991-12-16
US5576002A (en) 1996-11-19
FI19991917A7 (fi) 1999-09-09
IL96676A (en) 1996-09-12
SI20008A (sl) 2000-02-29
JP2637845B2 (ja) 1997-08-06
AU6898791A (en) 1991-07-18
CN1100656A (zh) 1995-03-29
CN1036504C (zh) 1997-11-26
FI19991917L (fi) 1999-09-09
YU24391A (sh) 1995-12-04
CN1049223C (zh) 2000-02-09
NO307835B1 (no) 2000-06-05
ATE121947T1 (de) 1995-05-15
IE68414B1 (en) 1996-06-12
CN1072506C (zh) 2001-10-10
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28

Similar Documents

Publication Publication Date Title
IL96676A0 (en) Improved meningococcal polysaccharide conjugate vaccine
GB8907914D0 (en) Vaccine preparation
HU896283D0 (en) Colon-selective, peroral medical preparation
EP0262876A3 (en) Nucleoside-phospholipid conjugate
GB8924438D0 (en) Vaccine composition
HUP9802664A3 (en) Modified meningococcal polysaccharide conjugate vaccines and modified polysaccharides
EP0454735A4 (en) Vaccine composition
GB8921470D0 (en) Vaccines
EP0468714A3 (en) Peptide-polysaccharide-protein conjugate vaccines
PT86286A (en) Conjugate vaccine
AU1118888A (en) Conjugate malaria vaccine
GB2232681B (en) Nitro-p-phenylenediamine derivatives
GB8918206D0 (en) Tuberculosis vaccine
GB8918689D0 (en) 25/15 vaccine
EP0504136A4 (en) Tolerogenic immunoglobulin-protein conjugates
GR3019065T3 (en) Vaccine Composition
HU9303207D0 (en) Liposomal polysaccharide vaccines
ZA907863B (en) Vaccine conjugate
ZA92536B (en) Pneumococcal polysaccharide conjugate vaccine
AU586857B2 (en) Klebsiella capsular polysaccharide vaccine
EP0453452A4 (en) Vaccine
ZA88792B (en) Conjugate malaria vaccine
GB8922651D0 (en) Vaccine
ZA90766B (en) Vaccine composition
GB8628286D0 (en) Polymer-peptide conjugate